Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CALM-AF-AI: Counteracting Age-related Loss of Muscle With AAV-Follistatin Combined With Angiogenesis-Inducing VEGF Plasmid Gene Therapy

NCT07443826 is registered in ClinicalTrials.gov with Unlimited Biotechnology LLC as lead sponsor.

NCT NCT07443826
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07443826 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CALM-AF-AI: Counteracting Age-related Loss of Muscle With AAV-Follistatin Combined With Angiogenesis-Inducing VEGF Plasmid Gene Therapy
Lead sponsor
Unlimited Biotechnology LLC
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 1, 2026
Completion date
June 30, 2028
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

age-related muscle decline